Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer

European Journal of Cancer Prevention

Volumn 19, Issue 4, 2010, Pages 288-292

  Tian, Wenjing ^a   Zhao, Yashuang ^a   Liu, Shengyuan ^b   Li, Xin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Shenzhen Nanshan Center for Chronic Disease Control   (China)

Author keywords

Aspirin; Gastric cancer; Meta analysis; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTHRITIS; ARTICLE; CANCER PREVENTION; CANCER RISK; CARDIA CARCINOMA; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; STOMACH CARCINOMA; STOMACH TUMOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 77953538362     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328339648c     Document Type: Article

References (59)

1. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A (2009). Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a metaanalysis. Br J Cancer 100:551-557.
2. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O (2001). Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 84:965-968.
3. Asano TK, McLeod RS (2004). Non-steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev (Online) 2:CD004079.
4. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899.
5. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG (2006). Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol 6:50.
6. Bax L, Yu LM, Ikeda N, Moons KG (2007). A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med Res Methodol 7:40.
7. Benamouzig R, Uzzan B, Little J, Chaussade S (2005). Low dose aspirin, COXinhibition and chemoprevention of colorectal cancer. Curr Topics Med Chem 5:493-503.
8. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. (2009). Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666-673.
9. Bonovas S, Filioussi K, Sitaras NM (2005). Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 60:194-203.
10. Bosetti C, Gallus S, La Vecchia C (2006). Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17:871-888.
11. Bosetti C, Gallus S, La Vecchia C (2009). Aspirin and cancer risk: a summary review to 2007. Recent results in cancer research. Fortschritte der Krebsforschung 181:231-251.
12. Brenner H, Rothenbacher D, Arndt V (2009). Epidemiology of stomach cancer. Methods Mol Biol 472:467-477.
13. Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ,Willett WC, et al. (2004). A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140:157-166.
14. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005). Long-term use of aspirin and nonsteroidal antiinflammatory drugs and risk of colorectal cancer. JAMA 294:914-923.
15. Choi AL, Cordier S, Weihe P, Grandjean P (2008). Negative confounding in the evaluation of toxicity: the case of methylmercury in fish and seafood. Crit Rev Toxicol 38:877-893.
16. Cibere J, Sibley J, Haga M (1997). Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580-1586.
17. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. (2009). Aspirin for the chemoprevention of colorectal adenomas: metaanalysis of the randomized trials. J Natl Cancer Inst 101:256-266.
18. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, et al. (2000). Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 9:119-123.
19. Duan L, Wu AH, Sullivan-Halley J, Bernstein L (2008). Nonsteroidal antiinflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 17:126-134.
20. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. (2007). The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Int Med 146:365-375.
21. Duval S, Tweedie R (2000). Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463.
22. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research ed) 315:629-634.
23. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN (2009). Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol 170:507-514.
24. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, et al. (1998). Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7:97-102.
25. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, et al. (2007). Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 5:1154-1159. e1153.
26. Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL, et al. (2004). Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 13:34-39.
27. Gatenby PA, Ramus JR, Caygill CP,Winslet MC,Watson A (2009). Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev 18:381-384.
28. Gillies M, Skyring A (1968). Gastric ulcer, duodenal ulcer and gastric carcinoma: a case-control study of certain social and environmental factors. Med J Aust 2:1132-1136.
29. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003). Effects of nonsteroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28.
30. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, et al. (2009). Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst 101:267-276.
31. Greenberg RS, Daniels SR, Flanders WD (2005). Medical epidemiology. 4th ed. New York: McGraw-Hill.
32. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. (1993). Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307-311.
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003). Measuring inconsistency in meta-analyses. BMJ (Clinical Research ed) 327:557-560.
34. Isomaki HA, Hakulinen T, Joutsenlahti U (1978). Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31:691-696.
35. Jolly K, Cheng KK, Langman MJ (2002). NSAIDs and gastrointestinal cancer prevention. Drugs 62:945-956.
36. Kelley JR, Duggan JM (2003). Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1-9.
37. Khan MI, Baqai MT, Bukhari M, Hashmi RI (2005). Gastric carcinoma: 5 years survival after gastric surgery. JAMA 55:158-160.
38. Khuder SA, Herial NA, Mutgi AB, Federman DJ (2005). Non-steroidal antiinflammatory drug use and lung cancer: a meta analysis. Chest 127:748-754.
39. Khushalani N (2008). Cancer of the esophagus and stomach. Mayo Clin Proc 83:712-722.
40. Kikuchi S, Katada N, Sakuramoto S, Kobayashi N, Shimao H,Watanabe M, et al. (2004). Survival after surgical treatment of early gastric cancer: surgical techniques and long-term survival. Langenbeck's archives of surgery. Deutsche Gesellschaft fur Chirurgie 389:69-74.
41. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000). Effect of antiinflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320:1642-1646.
42. Larsson SC, Giovannucci E, Bergkvist L,Wolk A (2006). Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:2561-2564.
43. Lindblad M, Lagergren J, Garcia Rodriguez LA (2005). Nonsteroidal antiinflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 14:444-450.
44. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J (2000). Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 36:390-396.
45. Nomura AM, Hankin JH, Kolonel LN,Wilkens LR, Goodman MT, Stemmermann GN (2003). Case-control study of diet and other risk factors for gastric cancer in Hawaii (United States). Cancer Causes Control 14:547-558.
46. Parkin DM (2006). The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030-3044.
47. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E (2004). Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24:3177-3184.
48. Rostgaard K (2008). Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. Epidemiol Perspect Innov 5:7.
49. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. (2007). Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Int Med 146:376-389.
50. Roukos DH (2000). Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26:243-255.
51. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC (2008). Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17:1169-1178.
52. Schreinemachers DM, Everson RB (1994). Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146.
53. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. (2003). Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687-1692.
54. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T (2000). H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 9:185-191.
55. Sutton AJ, Abams KR, Jones DR, Sheldon TA, Song F (2000). Methods for metaanalysis in medical research. United Kingdom: J Wiley.
56. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993). Aspirin use and risk of fatal cancer. Cancer Res 53:1322-1327.
57. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC (2003). Nonsteroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95:1784-1791.
58. Wang YP,Wang Q, Gan T, Pan T, Yang JL (2004). Non-steroidal anti-inflammatory agents for chemoprevention of colorectal polyps: a meta-analysis. Zhonghua nei ke za zhi [Chin J of Int Med] 43:10-12.
59. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V (1999). Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer 82:473-476.